Cellectar Biosciences, Inc. 2025 Annual Report: Key Investor Highlights

Ticker: CLRB
Exchange: Nasdaq Capital Market

Summary of Key Points

• Annual Report Filed: Cellectar Biosciences, Inc. (the “Company”, “Cellectar”) has filed its Form 10-K for the fiscal year ended December 31, 2025.
• Common Stock Outstanding: As of February 24, 2026, there were 4,240,129 shares of \$0.00001 par value common stock outstanding.
• Financial Health: The company reported a retained deficit of \$269.1 million and a net loss of \$21.8 million for 2025, with net cash used in operating activities totaling \$23.1 million.
• Nasdaq Listing: Shares continue to be listed on the Nasdaq Capital Market under the symbol CLRB, and the company affirms its ability to meet the continued listing standards.
• Filing Status: Cellectar is a non-accelerated filer and smaller reporting company, but not an emerging growth company.
• Regulatory Compliance: The company has filed all required reports and submitted all interactive data files as required by the SEC.
• No Shell Company Status: Cellectar is not a shell company.
• Forward-Looking Statements: The report contains forward-looking statements regarding business strategy, product development, funding, and market conditions.
• Price-Sensitive Risks: The report highlights risks such as funding needs, ability to execute development plans, supplier disruptions, economic instability, and potential impacts from legislative/regulatory developments.

Details That May Affect Share Value

1. Financial Performance and Cash Position

Net Loss: The company reported a net loss of \$21,791,037 for the year ended December 31, 2025.
Retained Deficit: Accumulated deficit stands at \$269,133,500, underlining the company’s ongoing cash burn typical of clinical-stage biotech firms.
Cash Used in Operations: Net cash used in operating activities was \$23,118,217, which may signal a need to raise further capital in the near future.

Investor Takeaway: The high cash burn and net loss might pressure the company to seek additional funding through equity, debt, or strategic partnerships, which could dilute existing shareholders or affect the share price.

2. Nasdaq Listing and Compliance

Compliance Affirmed: Cellectar confirms continued compliance with Nasdaq’s listing standards. This is significant because falling out of compliance could trigger delisting and negatively impact share value.

3. Regulatory and Filing Status

SEC Compliance: The company has met all SEC filing deadlines and requirements, including interactive data files. This reduces the risk of regulatory penalties or trading suspensions.

4. Capital Structure

Shares Outstanding: 4,240,129 shares as of February 24, 2026.
Common Stock Only: No securities registered under Section 12(g) of the Exchange Act; only the common stock is publicly traded.

Investor Takeaway: Any future equity raise could significantly impact the small float, potentially increasing volatility or diluting shareholders.

5. Forward-Looking Statements and Risks

• Statements cover business strategy, product development, and regulatory strategy.
• Risks include: ability to raise capital, execute development plans, supplier disruptions, and impacts from regulatory or economic changes.
• Ongoing risk of economic instability, legislative changes, and potential Nasdaq delisting if compliance lapses.

Investor Takeaway: These risks could materially impact the company’s stock price, especially if the company faces delays in clinical development, funding challenges, or regulatory setbacks.

6. Corporate Governance and Filing Structure

Non-Accelerated Filer / Smaller Reporting Company: Cellectar is not a large accelerated filer and does not have an auditor attestation of internal controls under Sarbanes-Oxley Section 404(b).

No Restatements or Shell Status: No error corrections or restatements were disclosed, and the company is not a shell.

Important for Shareholders

• Potential Dilution: The risk of future capital raises remains high, given the company’s cash usage and lack of profitability.
• Product Development Uncertainty: The future value is heavily dependent on clinical and regulatory milestones, which are inherently uncertain.
• Regulatory and Economic Risks: Legislative changes or macroeconomic factors could materially impact pricing, reimbursement, or the overall viability of product candidates.
• Nasdaq Listing Risk: Ongoing compliance is affirmed, but any future non-compliance could be highly price sensitive.

Conclusion

Cellectar Biosciences, Inc.’s 2025 annual report reflects a company in the high-risk, high-reward phase typical of clinical-stage biotech firms. Investors should closely monitor the company’s cash position, development progress, and compliance with Nasdaq and SEC regulations. The potential for future capital raises, clinical setbacks, or regulatory changes represents significant risks that could affect the share price.

Disclaimer: This article summarizes key financial and regulatory disclosures from Cellectar Biosciences, Inc.’s 2025 Form 10-K. Investors should review the full SEC filing and consult professional advisors before making investment decisions. This summary is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities.

View Cellectar Biosciences, Inc. Historical chart here